Zydus and MSN Shatter Adempas Monopoly, Bringing First Generic Riociguat to US Patients

In a major win for patients battling severe lung conditions, India's Zydus Lifesciences, in partnership with MSN Laboratories, has launched the first generic version of Adempas (riociguat) across five strengths in the United States. This breakthrough, announced on October 5, 2026, marks the end of Bayer long-standing monopoly on the crucial medication, promising a much-needed lower-cost treatment option for those suffering from pulmonary hypertension. Adempas, originally from German pharmaceutical giant Bayer, is vital for treating rare, progressive, and life-threatening conditions like Pulmonary Arterial Hypertension (PAH) and Chronic Thromboembolic Pulmonary Hypertension (CTEPH), which often require lifelong medication. With Bayer reporting global sales of Adempas around USD 850 million in 2025, the entry of a generic is set to shake up the market significantly. This 'first-to-market' generic launch underscores Zydus's growing prowess in developing complex generics and leveraging strategic partnerships like the one with MSN, who developed and manufactured the product. The introduction of generic riociguat is expected to intensify competition in the US pulmonary hypertension drug market, potentially leading to more affordable access for patients and easing healthcare burdens. For Zydus, this move strengthens its North America formulations business and highlights its strategy to target high-value, complex specialty segments. Healthcare providers and patients alike will now be closely watching the market for the impact of this new, more accessible treatment on patient outcomes and overall costs.